All In Biotech

Drug Trial Radar · NCT02368691

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

32

Actual

Start

Jun 2015

Primary completion

Sep 22, 2017

Study completion Sep 22, 2017

Sponsor

Lead sponsor
GTxIndustry
Sponsor type
Industry
First posted
Feb 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).

Conditions

  • Triple Negative Breast Cancer

Interventions

  • GTx-024Drug

    GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) SubjectsTime frame: Sixteen (16) weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Lakeland Regional Health Care/Cancer Center

    Lakeland, Florida

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • The West Clinic, PC

    Memphis, Tennessee

  • US Oncology / Texas Oncology, P.A.

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.